Yi Lang, Lin Guigao, Zhang Kuo, Wang Lunan, Zhang Rui, Xie Jiehong, Li Jinming
National Center for Clinical Laboratories, Beijing Hospital, Beijing 100730, P R China.
Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P R China.
PLoS One. 2016 Jan 28;11(1):e0148081. doi: 10.1371/journal.pone.0148081. eCollection 2016.
Irinotecan is widely used in the treatment of solid tumors, especially in colorectal cancer and lung cancer. Molecular testing for UGT1A1 genotyping is increasingly required in China for optimum irinotecan administration. In order to determine the performance of laboratories with regard to the whole testing process for UGT1A1 to ensure the consistency and accuracy of the test results, the National Center for Clinical Laboratories conducted an external quality assessment program for UGT1A128 genotyping in 2015. The panel, which comprised of four known mutational samples and six wild-type samples, was distributed to 45 laboratories that test for the presence of UGT1A128 polymorphisms. Participating laboratories were allowed to perform polymorphism analysis by using their routine methods. The accuracy of the genotyping and reporting of results was analyzed. Other information from the individual laboratories, including the number of samples tested each month, accreditation/certification status, and test methodology, was reviewed. Forty-four of the 45 participants reported the correct results for all samples. There was only one genotyping error, with a corresponding analytical sensitivity of 99.44% (179/180 challenges; 95% confidence interval: 96.94-99.99%) and an analytical specificity of 100% (270/270 challenges; 95% confidence interval: 98.64-100%). Both commercial kits and laboratory development tests were commonly used by the laboratories, and pyrosequencing was the main methodology used (n = 26, 57.8%). The style of the written reports showed large variation, and many reports showed a shortage of information. In summary, the first UGT1A1 genotyping external quality assessment result demonstrated that UGT1A1 genotype analysis of good quality was performed in the majority of pharmacogenetic testing centers that were investigated. However, greater education on the reporting of UGT1A1 genetic testing results is needed.
伊立替康广泛应用于实体瘤的治疗,尤其是结直肠癌和肺癌。在中国,为了优化伊立替康的给药,越来越需要对UGT1A1基因进行分子检测。为了确定实验室在UGT1A1整个检测过程中的表现,以确保检测结果的一致性和准确性,国家临床检验中心于2015年开展了UGT1A128基因分型的室间质量评价计划。该样本组由4个已知突变样本和6个野生型样本组成,分发给45个检测UGT1A128多态性的实验室。参与实验室可以使用其常规方法进行多态性分析。分析了基因分型和结果报告的准确性。还审查了各实验室的其他信息,包括每月检测的样本数量、认可/认证状态和检测方法。45个参与者中有44个报告了所有样本的正确结果。仅出现1例基因分型错误,相应的分析灵敏度为99.44%(179/180次挑战;95%置信区间:96.94-99.99%),分析特异性为100%(270/270次挑战;95%置信区间:98.64-100%)。实验室普遍使用商业试剂盒和实验室自行开发的检测方法,焦磷酸测序是主要使用的方法(n = 26,57.8%)。书面报告的格式差异很大,许多报告信息不足。总之,首次UGT1A1基因分型室间质量评价结果表明,在所调查的大多数药物遗传学检测中心,UGT1A1基因分型分析质量良好。然而,需要对UGT1A1基因检测结果的报告进行更多培训。